|
Lack of Bioequivalence Waivers for Generics Catches Congress’ Eye
Congress is starting to ask FDA officials questions about generic-drug makers’ ability to conduct bioequivalence (BE) studies on brand drugs in short supply, and the issue may be addressed in upcoming Generic Drug User Fee Act (GDUFA) authorization.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives